Fritextsökning
Artiklar per år
Innehållstyper
-
Tougher competition as the Novo Nordisk Foundation broadens its programme
Søren Nedergaard has worked with innovation at the Danish Government Offices and the University of Copenhagen. Today, he is COO of the Novo Nordisk Foundation, which has recently broadened its programme for leading innovators in medical research to apply to the entire Nordic region.
-
Björn Ursing: Physicians new role in AI driven healthcare
”AI could be the key we need for tomorrow’s healthcare, but it is not a stand-alone tool”, writes Björn Ursing in a column about how the role for physicians changes in the era of AI.
-
CAR-T therapies give continued hope: “Almost half of the patients have become disease-free”
When the first CAR-T therapies appeared, hopes were raised for the effective treatment for critically ill cancer patients. After a somewhat sluggish start, about 90 patients in Sweden have now been treated with this method. “Almost half of them have become disease-free, at least of those treated with Yescarta, which are the ones I know best,” says Gunilla Enblad, Chairman of the national working group for CAR-T treatment.
-
Anna Törner: Success requires bold decisions!
“Doing things right is fine, but doing the right things as soon as possible is even better”, writes Anna Törner in a column.
-
Sweden and Denmark – this is how they choose their strategies
Scandinavia’s two major powers in pharmaceutical research have developed strategies for growth in life science, and both countries aim to become world leaders.
-
Anna Törner: You won’t find this many Concorde projects anywhere else
"Suddenly Concorde projects seem reasonable in life science because it´s about life and death", writes Anna Törner in a column.
-
MVA:s CEO: “Our investments should improve people´s everyday lives”
Involuntary infertility and diabetes are two of the areas on the agenda of the Medicon Valley Alliance.
-
Column: Why there cannot be a complete cure for cancer – but there is certainly another way!
"Is there a new way we need to be thinking about how to prevent cancer?" Lucy Robertshaw reflects upon which is the smartest way to beat cancer.
-
Björn Arvidsson: Let's build on the positive momentum
Progress needs narratives and heroes, and more than ever, going into the new year feels like an opportunity for a fresh start.
-
Sjöbergpriset går till nyupptäckt mekanism för cancerläkemedel
Benjamin L. Ebert får priset för sin forskning om ämnet lenalidomid och dess betydelse vid behandling av blodcancer.
-
Column: Repurposing as a golden ticket to approval
"Hopefully, in the end, patients will be winners by receiving on-label treatments for which benefit-risk has been properly assessed." In a column Marie Gårdmark, CEO at RegSmart Life Science, reflects on drug repurposing.
-
Samuel Lagercrantz: Collaboration and joint efforts are the key to success
Although many questions about Covid-19 remain unanswered, the development of drugs and vaccines has been incredibly rapid, writes Samuel Lagercrantz, Life Science Sweden´s Editor-in-Chief, in an editorial.
-
Column: "Are we already living in the new normal?"
2020 felt like the year that we were building the house around us whilst moving into it at the same time.
-
Spetsteknologi utvecklad i samarbete med forskare – framgångsrecept på vägen till nya läkemedel
Varje år analyserar forskare från hela världen miljontals molekyler för att identifiera nya potentiella läkemedel. I tre decennier har Biacore™ ytplasmonresonans-tekniken bidragit till forskning och utveckling av nya läkemedel.
-
New diagnostic test soon ready for the market
-
Combining two drug delivery strategies to improve bioavailability
Danish researchers hope to increase the bioavailability of low solubility drugs.
-
Marie Gårdmark: Do EMA and FDA talk to each other?
Of course they do! The collaboration started already in 2003, writes Marie Gårdmark in a column.
-
Giulia Gaudenzi: ”Key lessons from global health research”
The world will still face major challenges in the post Covid-19 pandemic, writes Giulia Gaudenzi at the KTH Division of Nanobiotechnology at Scilifelab, in a column.
-
Helena Strigård: The rise of the community
Sweden Bio´s CEO is looking back at the last decade of development in the industry. Something has shifted in the interdependence between small and larger companies.
-
Pilots want to live too
-
Coordination of world-class research facilities
Four unique world-class research facilities are located just a few hours apart. Properly utilised, a Nordic centre for world-leading life science innovation and research could become a reality. Kajsa M Paulsson is the project leader for HALOS, driving the idea forward.
-
Engage with your CMO early
Gordon Hutton is Materials Science Lead at Thermo Fisher Scientific’s, formerly GSK, small molecule API site in Cork, Ireland.
-
From spin-off to phase II
”The people there will basically become your new colleagues” – Carina Schmidt, former CEO of Athera, about working with different contractors.
-
Before you choose a CRO
– We are a small company and it is very important for us to maintain our core competence within development of novel nanomaterials, Tove Sivik Sonne, Head of Development at Spago Nanomedical says.